Life Sciences & Biotechnology

Title :

Combating the Undruggable Ternary EGFR L858R-T790M-C797S Mutation Associated with Osimertinib for the Treatment of Non-Small Cell Lung Cancer (NSCLC)

Area of research :

Life Sciences & Biotechnology

Focus area :

Pharmaceutical chemistry

Principal Investigator :

Dr. Harun M. Patel, Associate Professor, R.C. Patel College of Pharmacy, Shirpur

Timeline Start Year :


Timeline End Year :


Contact info :


Executive Summary :

The US FDA approved Osimertinib (AZD9291) for treating metastatic EGFR-T790M NSCLC. However, a significant number of patients developed a C797S mutation, rendering Osimertinib resistant. This suggests a need for drugs to overcome this resistance obstacle. The current proposal focuses on designing and synthesizing fourth-generation triple mutant selective EGFR-L858R-T790M-C797S tyrosine kinase inhibitors to overcome this resistance in NSCLC chemotherapy.

Total Budget (INR):


Organizations involved